Today: 10 June 2026
Browse Category

NASDAQ:SUPN 25 February 2026

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 25.02.2026

Supernus Pharmaceuticals reported Q4 earnings of $0.92 per share, beating the Zacks estimate of $0.28. Revenue rose to $211.57 million from $174.16 million a year earlier. The company has topped consensus estimates for four straight quarters. Shares are up 2% year-to-date, but the stock holds a Zacks Rank #5 (Strong Sell) due to negative earnings estimate revisions.
25 February 2026
·

Stock Market Today

  • Taiwan Stock Exchange Surges but Economic Disparities Persist
    June 10, 2026, 9:17 AM EDT. Taiwan's stock market, the Taiwan Stock Exchange Corporation (TWSE), has soared to become the world's fifth largest by market capitalization, driven primarily by firms linked to the global AI boom. Despite this, economic fundamentals tell a more complex story. Taiwan's GDP in 2025 reached over TWD 26 trillion, supported by private consumption, government spending, investment, and net exports. However, the stock market's valuation at TWD 150 trillion far outpaces GDP, reflecting investor optimism rather than comprehensive economic health. Challenges such as uneven wage growth, trade shocks, and affordability issues remain unaddressed. Analysts warn that relying solely on stock market figures risks overlooking these structural economic disparities and potential instability in Taiwan's broader economy.

Latest articles

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

BlackBerry Drops Again; QNX Gains on the Line With June Earnings Ahead

10 June 2026
BlackBerry shares dropped 4.84% to $8.84 Tuesday and slid further to $8.42 premarket Wednesday, erasing part of a 49% rally as investors question whether QNX and Secure Communications growth can justify recent gains ahead of Q1 fiscal 2027 earnings on June 25; the stock is now down 14.5% from last week’s close.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

10 June 2026
Nuvalent soared 39.28% to $123.25 after GSK agreed to buy the company for $124 per share in cash, leaving a narrow 0.6% spread as investors shift focus to the $10.6 billion merger’s tender-offer timing, antitrust review, and FDA decision dates for two lung-cancer drugs in September and November 2026.
Go toTop